Six top tips to prepare for the new EU Clinical Trial Regulation
The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026